Thanks for this update. Merry Christmas to you

Update 5:55pm PST

Dear Cary, Thanks for your ongoing support and participation. We are waiting for an update from our financial team on the 10-Ks and 10-Qs and should have more information next week. The audit is on schedule and is following the industry standard 8-12 weeks per fiscal year. We are filing all of the 10-Ks and 10-Qs in a single filing rather than year by year, which explains the current timeline. Best wishes to you and your family for a happy holiday season and a prosperous New Year. Thanks, Mark

Hey TravO - this was sent to me at around 9PM PST tonight

Dear Cary, Thanks for your ongoing support and feedback. The financials are on schedule. We will announce the filing date for the 10-Ks and 10-Qs with a formal press release. Thanks, Mark

Address it to him via email. It's his remarks not mine. I wasn't clear on his response either

Dear Cary, Thanks for your support and positive feedback. The strategy is to file all the 10-Ks and 10-Qs in a single filing. The standard time of 8-12 weeks per fiscal year applies and the financials are on schedule. Thanks, Mark

Hey Ace -

Got your PM. Sorry I don't have private messaging - but to answer your question YES ABSOLUTELY. All devices down to the tubes, viles, etc have to be FDA approved

For strategic reasons and for reasons related to non-disclosure, healthcare confidentiality and the like, our investor relations team evaluates the level of detail to include in each press release and issues the PR accordingly. -Mark

https://www.rocketlawyer.com/article/nda-101:-what-is-a-non-disclosure-agreement.rl

https://www.investopedia.com/terms/n/nda.asp

Thanks for this update!

Here's a quick update from Mark:

Hi Mark –

Thanks for all your updates and replies. Given the PR today, it’s not what a lot of us were expecting or still anticipating – which is the financials but we are continuing to be patient. I know you can’t answer any questions regarding when, but with 3 weeks remaining of Fall 2018, we are very anxious about getting the financials done. I think a lot of us were anticipating some sort of announcement this morning being a PR day, but I really hope that “Fall 2018” is still a goal that won’t be pushed to Spring 2019.



Dear Cary, Thanks again for your support and feedback. Filing the 10-Ks and 10-Qs is a top priority. We will issue a formal press release announcing the filing date. We appreciate your patience. Thanks, Mark

Mark Schena, Ph.D.
President
Arrayit Corporation (ARYC)



As usual - don't bother replying if it's yet another baseless negative complaint. Thanks

Thanks for sharing P4K! Process for uplisting is exciting and possibly explains why RRBB has advised against releasing the (internally current) financials publicly until other things are in place. Who knows? I'm just glad I'm a long holder like many here

Thanks for the email TravO. Great information as usual

Thanks for sharing, Raspaman!

My thoughts as well BillyBob.

Happy Thanksgiving! No other company in the OTC with this many legitimate partnerships and this price right now. See you in dollar land

You're welcome Ace! Happy Thanksgiving to you and your family

For the longs, here's a Mark update:

Dear Cary, Thanks for your support and positive feedback. Our Sutter sales representative is meeting with Kaiser on an ongoing basis, so hopefully we will sign Kaiser soon. We appreciate the kind words. Happy Thanksgiving! Mark


Don't bother responding if it's yet another complaint.

I sent Mark an email this morning along with sending him and his family well wishes for this Thanksgiving holiday. I'll keep you posted with his response. I'm rarely on this board due to my low tolerance for idiotic, impatient posters. Financials are coming. In the meantime, I'm watching my other investments and moving on with everything else I'm thankful for in my life instead of sitting here complaining about things beyond my control. Happy Thanksgiving to you and your family, PTC

Thanks for the correction, Mike. I thought perhaps the deal included food intolerance along with the allergy testing - selective/hopeful vision I suppose.

Just want to add that the pinnertest doesn't just help confirm allergies but is also used to diagnose food intolerances. IMO its use will extend beyond giving patients allergy results. At KP, our preventative health programs have a ton of nutrition and dietary classes. If these tests were to be used to address food intolerances, we would be able to design specific food plans for each individual patient. IMO this is a lot bigger than just testing for allergies

Hey Antbird, thanks for the response! As far as which department to approach about this deal, I would think of the following I would ask myself:

Program Manager for Allergy Department: Ask specifics of how the test is presented as an option for patients

Lab Department: Since our organizations already have our own CLIA licensed labs - do we purchase the processing equipment from Arrayit to do the analysis ourselves or do we still depend on the patients to send the cards to Arrayit's lab? Either way, I just don't think Arrayit's lab will be able to handle the massive amounts of blood cards that come in from our millions of patients. I would think our organizations would purchase the equipment and training (ie $$$$$) from Arrayit to be able to process the blood cards on our own. This is something I hope longs are thinking about as well.

Department of infectious diseases: if Sutter is committed to IgE blood card testing with Arrayit - does that open doors to Arrayit's other diagnostic products? Why was a deal signed prior to FDA approvals? Does Sutter know something we don't? :)

I will be on and off from IHUB. I can't stand the constant complainers who can't see the big picture. Have a great Thanksgiving Antbird

Last time ARYC released a PR in the middle of the week was 18 days ago. I understand the scheduled bi-weekly Monday PRs but I don't think the financials announcement has to necessarily be on that same pattern. Just sayin

I'm impatient too but I always ask myself this...If large organizations keep doing business with Arrayit and none of them have come forward to dispute the public announcements of deals, purchases, or invitations... Then something has to be legit. There's just too much factual evidence to imply their intentions of listing to NASDAQ rather than being in the OTC much longer

And UCSF as well along with Stanford Medical IMO

I work for Kaiser Permanente and IMO, no there aren't deals like this already in place with organizations of this magnitude. Probably small private clinics but not massive health Care organizations like this. Reason is they (large orgs) signed deals with allergy tests where the patients have to come in and either do a full lab blood draw or skin tests with multiple pricks - and in turn process those lab tests in their own CMS/CLIA licensed labs. This is the first I've ever heard of a large org signing a deal where the patient can just mail in their blood drops to a 3rd party CLIA licensed lab. A lot of people don't realize how massive this news is and the implications it has towards FDA approvals IMO

Antbird, as an employee of a competing organization, let me be the first to congratulate your company (Sutter) on this massive deal with Arrayit!! I'm hoping Kaiser Permanente will sign their respective deal soon too!

Thanks for the reminder

Here's the earnings calendar for the next couple of weeks:

https://m.nasdaq.com/earnings/earnings-calendar.aspx

From Mark just now:

Dear Cary, We appreciate your support and feedback. The filing date will be announced with a formal press release followed by a tweet. Thanks, Mark


http://arrayit.com/index.html

I agree with that reasoning. Makes sense absolutely why they would push it back. I think they believed that the erroneous audits that Moss Krusick did previously hurt their business and they want to make sure it's done more accurately this time with RRBB

I didn't believe it when I bought for .0072 that it would be steadily holding at .06 :)

It was all speculation when fins will be released. A lot of people collectively believed based on end of Q3 deadline and Taub lawsuit that it would be very soon. Arrayit's quiet period never stated when. The ONLY official thing aside from the quiet period is:

"We will resume quarterly and annual financial filings during the fall of 2018."

The end of fall is officially December 21st. I realized they missed the summer 2018 deadline - but they DID update the website to Fall 2018.

Tweet from Halloween: Arrayit provides an update to shareholders. We are currently in (spell correction from "is") a quiet period regarding our financials. Our next financial announcement will be the filing of our 10-K and 10-Q forms through 2018. Thanks everyone for your continued support and patience! http://arrayit.com/index.html

Hoping for more treat than tricks...

Agreed, Ace. All great signs to look for. All weak arguments against ARYC will be silenced soon.

Agreed BZ. The beauty of this it's that two things will disappear when financials get here: The CE on otcmarkets and the trolls from this forum.

Very well said. No other company with this much going on before financials even hit soon

It's great that the fpds website combined all of Telechem's past contracts with Arrayit so you can see their long history of business with the US government alone:

https://www.fpds.gov/ezsearch/search.do?q=arrayit&s=FPDSNG.COM&templateName=1.4.4&indexName=awardfull&sortBy=SIGNED_DATE&desc=N

Yup we're on Epic as well - and yes the data integration between healthcare orgs is a huge project for everyone

Don't let negative talk distract you. IMO, AFFXs history will repeat itself with ARYC. They also had many doubters who missed out and probably sold at $3 before the stock hit $14 upon purchase from Illumina. Also interestingly, look who's done business with AFFX. Look familiar?



Here's an old PR from Affymetrix:

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq:AFFX - News) today announced that the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California at San Francisco (UCSF) have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members.

The members have volunteered for a large-scale research program designed to create a new resource for studying disease, health, and aging. Scientists from the program will use the just-launched Axiom Genotyping Solution, which delivers high-throughput, automated technology and enables researchers to find novel and common genetic variations associated with complex disease.

DNA studies will be linked to Kaiser Permanente’s electronic health record system, the largest of its kind. Information from health surveys and environmental data will also be analyzed. These resources will give researchers an entirely new platform for studying genetic and environmental influences over time on a wide variety of health conditions, across diverse populations.

The program is being funded by a $24.8 million grant from the National Institutes of Health (NIH)1, and over the next two years, a significant portion of this amount is expected to be used to purchase the Axiom Genotyping Solution.

The Kaiser Permanente RPGEH is a growing resource for scientific research designed to facilitate epidemiologic studies of both genetic and environmental influences on common health conditions, such as heart disease, diabetes, cancer, asthma, mental health disorders, and many others.

“The NIH grant gives Kaiser Permanente and UCSF an opportunity to utilize a new model for studying human genetics,” said Kevin King, president and CEO of Affymetrix. “We greatly value the relationship we have built with the program leaders over the last two years, and we are excited that our technology will be used to help researchers study effective prevention and treatment strategies to improve healthcare and quality of life.”

The Axiom Solution is configured to continually validate and incorporate the output of large-scale sequencing projects. Initial offerings are designed from public databases of human variations and cover historical HapMap data supplemented by subsequent releases of additional variants. In addition, Affymetrix is screening millions of putative SNPs and insertions/deletions that are being discovered by the 1000 Genomes Project and other sources, and will make these available to researchers using the Axiom Solution.

The solution consists of Axiom Array Plates, complete Axiom Reagent Kits, an automated target preparation station developed jointly by Affymetrix and Beckman Coulter, plus the GeneTitan™ Multi-Channel (MC) Instrument. The GeneTitan MC Instrument integrates a hybridization oven, fluidics processing, CCD imaging device, and analysis software for maximum data reproducibility, user productivity, and scalability.

A small company founded in 1992 called Affymetrix used to be located 5 miles from Arrayit's HQ. They were a similar company founded by a brilliant doctor. His name is Dr. Stephen Fodor. He specialized in DNA microarrays and gene expression. In January 2016, Affymetrix was bought by Illumina for 1.3 billion dollars. Yes. It took 24 years for this company to be finally purchased.

What does this have to do with Arrayit? Well Arrayit was founded in 1999. Dr. Mark Schena has written and published 4 books about Protein Microarrays. At the time the use of protein microarrays seemed like a step-child behind DNA microarrays, but their use has grown since then and are becoming more and more important in the world of diagnostics. This year is Arrayit's 19th year in existence. Many doubt Mark's business decisions but no one can deny his credibility with the science behind Arrayit. Will you be here in Arrayit's 24th year or will you read about it being purchased later on? Up to you.